Stem cell transplantation for immunoglobulin light chain amyloidosis

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Systemic chemotherapy aimed at eradicating transformed plasma cells is the mainstay of treatment for immunoglobulin light chain amyloidosis (AL). Autologous stem cell transplantation (SCT) is a highly effective treatment for AL and can lead to long term survival in excess of 10 years in patients who achieve complete remission. Since AL is a unique disease characterized by multiple organ dysfunction, SCT poses unique challenges in this disease. Morbidity and mortality of SCT has remarkably improved over time primarily due to careful selection of patients and evolution of predictive and prognostic models based on serum immunoglobulin light chains and cardiac biomarkers. In this review we focus on the historical evolution of SCT as a treatment for AL and unique challenges it poses in the management of this rare disease and provide guidelines for managing these challenges.

Original languageEnglish (US)
Pages (from-to)129-137
Number of pages9
JournalCurrent Problems in Cancer
Issue number2
StatePublished - Mar 2017


  • AL
  • Immunoglobulin light chain amyloidosis
  • Stem cell transplantation
  • Stem cell transplantation for AL

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Stem cell transplantation for immunoglobulin light chain amyloidosis'. Together they form a unique fingerprint.

Cite this